Korea National Health Insurance Database review shows that risk of mortality in Behcets patients is 28% higher than gen. population; highest in 1st 12 mos (OR 2.66). Major causes were CA, CVD, GI (viscus rupture), respiratory, & infections. Higher in younger pts. https://t.co/vWJrUN9C0H

MD Anderson Cancer Center study of 1991 RA pts w/ prostate, lung or colon cancer showed TNFi use in 1st 3yrs did NOT affect survival. Use of TNFi vs csDMARDs - nonsign lowering in CRCA (HR 0·72;0·43–1·21), Lung CA (0·70;0·49–1·00), Prostate CA (0·80;0·44–1·44) https://t.co/8zJ0OBWjbm

If COVID was responsible for causing autoimmune Dz (AD), it is possible that Molecular mimicry was in play. Study shows 10nsequence homology between SARS-CoV-2 & AD epitopes; 2) similar MHC binding; 3) of high empirical immunogenicity. https://t.co/WO3gjxhVBw https://t.co/QdqtQMHcpL

• Molecular mimicry impact of the COVID-19 pandemic: Sequence homology between SA…

Researchers have developed a machine learning model capable of predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis. In the KURAMA cohort of 210 SN patients, 57 (27%) progressed to RA. The FNN model excelled with an AUC of 0.924 and 81% https://t.co/b8G2AzMZ7m

Phase 3 RCT shows that SC Abatacept was not effective in treating Active Idiopathic Inflammatory Myopathy: 148 (double-blind) & 133 (OL) pts Rx for 24wks with similar improvement 56% ABA vs 42.5% PBO (P = 0.083); NS at 52 wks & w/ dermatomyositis. https://t.co/InlHJSmiKn https://t.co/mtFQWp3vlb

• Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Activ…

EUSTAR database study of 17,805 scleroderma (SSc) pts, 468 (2.6%) used HCQ with no effect on or improvement on HAQ-DI, or hand function scores when comparing HCQ users to non-HCQ users. https://t.co/Tu4tfG74pn https://t.co/Kckx3zTiJ4

• The effect of hydroxychloroquine on activities of daily living and hand functio…

Fresenius Receives FDA Approval for their Denosumab Biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) based on reference products: Prolia (denosumab) and Xgeva (denosumab) respectively. US launch mid-2025 https://t.co/0i5ZMJSxnp https://t.co/zeQ7QhmA0n

• Fresenius Receives FDA Approval for their Denosumab Biosimilars and Secures Glo…

Rheums! Have a rheumatology question or case for Dr.Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/VkPL7thzo8 https://t.co/h85iF6tIVk

• Submit Podcast Question or Comment | RheumNow

Full read review on inflammatory myositis (Patient or med student level knowlegdge) Epidemiology Risk Factors Prognosis Sxs, Dx, Differential Dx Treatment Complications Myositis Guidelines https://t.co/s0LtHyYeuS https://t.co/lMEpMIotSP

• Myositis

Missed RheumNow Live but still want the great coverage? For the first time ever, https://t.co/4UQlqwujiR 2025 is Available On Demand! ✔️ STEP Talks from top rheumatologists ✔️ Lectures on the biggest clinical challenges ✔️ Speaker slides and handouts you’ll use Non-CME, https://t.co/lns8EQBZjw

• RheumNow

Worse Outcomes in HLA-B27+ JIA Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term outcomes, including lower rates of drug-free remission, in a prospective Scandinavian study. https://t.co/VEKqHvO1qw https://t.co/49y0JQL0Gr

• Worse Outcomes in HLA-B27+ JIA | RheumNow